Mohammed Chrysan J, Xie Yanmei, Brewster Pamela S, Ghosh Subhanwita, Dube Prabhatchandra, Sarsour Tiana, Kleinhenz Andrew L, Crawford Erin L, Malhotra Deepak, James Richard W, Kalra Philip A, Haller Steven T, Kennedy David J
Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Department of Internal Medicine, Geneva University Hospital, 1205 Geneva, Switzerland.
J Clin Med. 2019 Jul 15;8(7):1034. doi: 10.3390/jcm8071034.
The burden of cardiovascular disease and death in chronic kidney disease (CKD) outpaces that of the other diseases and is not adequately described by traditional risk factors alone. Diminished activity of paraoxonase (PON)-1 is associated with increased oxidant stress, a common feature underlying the pathogenesis of CKD. We aimed to assess the prognostic value of circulating PON-1 protein and PON lactonase activity on adverse clinical outcomes across various stages and etiologies of CKD. Circulating PON-1 protein levels and PON lactonase activity were measured simultaneously in patients with CKD as well as a cohort of apparently healthy non-CKD subjects. Both circulating PON-1 protein levels and PON lactonase activity were significantly lower in CKD patients compared to the non-CKD subjects. Similarly, across all stages of CKD, circulating PON-1 protein and PON lactonase activity were significantly lower in patients with CKD compared to the non-CKD controls. Circulating PON lactonase activity, but not protein levels, predicted future adverse clinical outcomes, even after adjustment for traditional risk factors. The combination of lower circulating protein levels and higher activity within the CKD subjects were associated with the best survival outcomes. These findings demonstrate that diminished circulating PON lactonase activity, but not protein levels, predicts higher risk of future adverse clinical outcomes in patients with CKD.
慢性肾脏病(CKD)中心血管疾病和死亡的负担超过了其他疾病,仅靠传统风险因素无法充分描述这一情况。对氧磷酶(PON)-1活性降低与氧化应激增加有关,氧化应激是CKD发病机制的一个共同特征。我们旨在评估循环中PON-1蛋白和PON内酯酶活性对不同阶段和病因的CKD患者不良临床结局的预后价值。同时测量了CKD患者以及一组明显健康的非CKD受试者的循环PON-1蛋白水平和PON内酯酶活性。与非CKD受试者相比,CKD患者的循环PON-1蛋白水平和PON内酯酶活性均显著降低。同样,在CKD的所有阶段,与非CKD对照组相比,CKD患者的循环PON-1蛋白和PON内酯酶活性均显著降低。即使在调整了传统风险因素之后,循环PON内酯酶活性而非蛋白水平可预测未来的不良临床结局。CKD受试者中较低的循环蛋白水平和较高的活性相结合与最佳生存结局相关。这些发现表明,循环PON内酯酶活性降低而非蛋白水平可预测CKD患者未来发生不良临床结局的较高风险。